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Abstract
The purpose of this research was to identify the best course of action in response to a diagnosis
of unprovoked pulmonary embolism. This meta-review was compiled through a systematic query
of four databases: Pubmed, Embase, CINAHL Complete, and Cochrane Review. The search was
limited to peer-reviewed systematic reviews published between October 1, 2014, and October 1,
2019. 17 reviews were included in this research which evaluated relevant trials of FDA-approved
anticoagulation therapies. Key search terms that were used included anticoagulation,
unprovoked, and duration. MeSH terms applied on PubMed included anticoagulation, therapy,
and duration. The evidence demonstrates non-inferiority status of new direct oral anticoagulants
(DOAC) when indirectly compared to conventional warfarin therapy. Aspirin was also found
effective in mitigating the risk of recurrence, but to a lesser extent than both DOAC agents and
warfarin. Current research demonstrates all DOAC agents as potential alternatives to
conventional therapy, but attention to the comorbidities of each individual patient may direct
providers to find advantage with one therapy over another. The research, thus far, has not been
able to identify a universally safe and an effective agent for all patients experiencing a first-time
unprovoked pulmonary embolism. Additional research is needed to evaluate the duration of
therapy and generate more robust data to recommend a specific therapeutic agent for all patients.
Keywords: anticoagulation, unprovoked pulmonary embolism, warfarin, direct oral
anticoagulants, aspirin, anticoagulation duration
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Introduction
Preventing pulmonary embolism recurrence, has generated a tremendous amount of
interest and debate in recent years. The development of Direct Thrombin Inhibitors (DTI), and
Factor Xa Inhibitors (FXI) collectively known as the direct oral anticoagulation drugs (DOAC),
have become replacement agents for conventional therapy. Traditional anticoagulation agent,
Warfarin, a vitamin K antagonist (VKA), has been the primary drug of choice for PE treatment,
but due to its increased bleeding risk therapy duration was limited. The traditional VKA
alternative was acetylsalicylic acid or Aspirin (ASA) which provides only a fraction of the
benefit while marginally mitigating the bleeding risk. These DOACs do provide an additional
choice for providers but are questionable alternatives to conventional therapy. Another concern
for providers to consider is the duration of therapy, as termination of anticoagulation therapy
places patients back into a high-risk category.
Statement of the Problem
First-time unprovoked pulmonary embolism presents a difficult choice for recurrence
prevention. Etiology of the insult is unknown, and prevention of recurrence is of utmost
importance, but with treatment comes increased risk, primarily bleeding episodes. A provider
must address each unprovoked PE patient on an individual basis and evaluate risk/benefit
individually. This research is designed to help providers choose the best course of action for PE
recurrence prevention while mitigating risk.
Research Question
Does drug choice and treatment duration impact morbidity and mortality for first-time
unprovoked pulmonary embolism?
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Methods
This review was compiled through a systematic review of Pubmed, Embase, CINAHL
Complete, and Cochrane Review databases. The search was limited to peer-reviewed systematic
reviews published within the past five years with the cutoff date October 1, 2014. Only human
trials include this review. Studies reviewed were restricted to North American and European
countries, as well as Australia, and China. These countries provide similar demographics and
prevalence of disease. Key search terms that were used included anticoagulation, unprovoked,
and duration. MeSH terms applied to PubMed included anticoagulation, therapy, and duration.
Two additional studies, a 2013 Caststelluci et al. meta-analysis and a 1997 Schulman et al. study,
were cited. Both citations were published outside of the established time parameters and added to
illustrate the risks and benefits of warfarin therapy. All studies that included cancer patients,
antiphospholipid syndrome patients, atrial fibrillation, post-operative patients, and all heparin
therapy were excluded from the included literature review.
Safety and Efficacy of Aspirin
Two separate trials examined the efficacy and safety of aspirin, as monotherapy in
recurrence prevention of pulmonary embolism: the WARFASA and ASPIRE studies. These two
studies were specifically designed to be pooled upon completion, titled INSPIRE. The
independent studies were designed with strict International Normalized Ratio (INR) adherence
between 2.0-3.0 through lead-in warfarin therapy. The duration of lead-in therapy varied amongst
participants ranging from 6-18 months. Designated follow-up for WARFASA was at 24 months
and at four years in the ASPIRE trial. The studies classified the primary outcome as reported
venous thromboembolism (VTE) recurrence and the secondary outcome as safety, which was
reported as bleeding episodes.
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A 2016 Bauersachs review concluded the WARFASA trial demonstrated aspirin efficacy
over placebo with a reported VTE recurrence of 6.6% versus 11.2% in the treatment group and
placebo group respectively, p= 0.002. There was a relative risk reduction of 41% when primary
and secondary outcomes were compared. The WARFASA trial reported one bleeding death and
three non-fatal but qualifying bleeding episodes.
ASPIRE showed no statistically significant differences in the primary outcome between
the treatment group and placebo 4.8% versus 6.5% respectively, p= 0.09. The secondary outcome
was consistent between groups in the WARFASA trial results. The average follow-up in ASPIRE
was 37.5 months after therapy initiation. One incidental finding of ASPIRE was the potential
cardioprotective component of daily aspirin therapy. There was a 34% reduction in reported
major cardiovascular events (composite VTE, myocardial infarction, stroke, or cardiovascular
death), p=0.01(Bauersachs, 2016).
A retrospective cohort study (Boonyawat, 2015) of 1,919 clinical charts showed
contrasting real-life effects of aspirin in preventing recurrent VTE. 256 of the reviewed charts
demonstrated atherosclerosis and were subsequently placed on daily aspirin ranging from 80-160
mg. The remaining patient charts reviewed did not receive aspirin. Follow-up of these patients
indicated a 17.2% recurrence risk in the treatment group versus 19.8% in the non-atherosclerotic
group. There is no reported bleeding risk evaluation for this retrospective cohort study.
As of this review, only one study (Carmen 2018) has examined aspirin directly against a
direct oral anticoagulant. The EINSTEIN-choice was an extension of the EINSTEIN Program
examining the efficacy of rivaroxaban. In this trial, aspirin was measured against two daily doses
of rivaroxaban: 20 mg and 10 mg. The study authors reported the highest primary outcome
within the aspirin arm at 4.4%, whereas rivaroxaban arms reported recurrence at 1.5% and 1.2%
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in 10 mg and 20 mg respectively, p< 0.001. All three trial arms showed non-statistically
significant differences in the bleeding risk (Carmen 2018).
Safety and Efficacy of Conventional Therapy
In the Bauersachs (2016) review, he evaluated several prior studies to illustrate the safety
and efficacy of warfarin therapy during treatment of recurrent VTE. He cites a 2013 Castellucci
meta-review showing an 8.8% reduction per year in treatment groups over placebo. The same
study showed a 1.3% increase in bleeding risk in the treatment over placebo. However, a 1997
Schulman study showed an 8.6% increase in bleeding risk at a four-year follow-up in the
treatment group over control. This study also verified therapeutic benefits of warfarin were only
conveyed to the treatment group, as the control group reported a higher incidence of recurrent
VTE (Bauersach, 2016). In a review by Castellucci, de Witt, Garcia, Ortel, & Le Gal (2018) of
the 2015 PRADIS-RE trial, the reviewers confirmed the therapeutic benefits of warfarin are only
conveyed to the recipient while actively receiving the medication. The risk of recurrent VTE
returns to baseline upon discontinuation of therapy (Castellucci et al., 2018).
Castellucci et al. analysis of the RE-MEDY trial, which directly compared warfarin to
another anticoagulant agent, dabigatran, demonstrated non-inferior status between these two
medications, but a marked difference in their safety profiles. The study showed a 1.3% reported
recurrence in the warfarin group and 1.8% in the dabigatran group, p= 0.01. This study also
demonstrated the increased safety profile of dabigatran over warfarin with 13 reported major
bleeds in the dabigatran group versus 25 within the warfarin group. The warfarin group reported
higher rates of clinically relevant bleeding at 145 (10.2%) versus 80 (5.6%) in the dabigatran
group. (Catellucci et al., 2018)
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A meta-analysis performed by Jiang et al. (2018) evaluated studies comparing low dose
warfarin to both placebo and conventional-dose warfarin. All patients included in this evaluation
were diagnosed with first time unprovoked pulmonary embolism and all received at least three
months of conventional-dose warfarin prior to beginning low-dose trial. All four studies reported
reduction in the primary outcome with conventional therapy (INR 2.0-3.0) being more
efficacious than low-dose therapy (INR 1.5-1.9), but both demonstrating superiority over
placebo. Recurrent VTE occurred in 27 of the 706 patients (3.8%) treated with low-intensity

warfarin and in 9 of the 693 patients (1.3%) treated with conventional-intensity warfarin.

Another study Jiang et al. (2018) review demonstrated out of 369 patients assigned to lowintensity therapy, 16 had VTE (1.9 per 100 person-years), as compared to 6 of 369 assigned to
conventional-intensity therapy (0.7 per 100 person-years); HR, 2.8.
Safety and Efficacy of Direct Oral Anticoagulants
Direct oral anticoagulant (DOAC) therapy is a broad and general term to describe
multiple classes of anticoagulant agents. This group consists of direct thrombin inhibitors (DTI)
like dabigatran and factor Xa inhibitors, like rivaroxaban, edoxaban, and apixaban. Both groups
inhibit specific targets within the clotting cascade. Multiple studies and meta-analysis examined
data which establishes the efficacy of DOACs versus placebo. The primary goal of the individual
studies was to determine how well do these medications work to prevent recurrence of a
pulmonary embolism as well as assessing the risk associated with anticoagulation.
A Bauersach (2016) review looked at rivaroxaban, apixaban, and dabigatran studies.
These studies compared a single agent to a placebo. Lead-in therapy agent and duration varied
amongst the trials. Therapy duration varied between 6-18 months. Results indicate DOAC as
efficacious, or non-inferior, to warfarin with primary outcome reported as 0.4-1.2% for
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recurrence in treatment arms and 5.6-8.8% in the placebo arms. Safety outcomes in this review
indicate similar outcomes with reported bleeding and bleeding mortality 0.1-0.7% for the
treatment arm versus 0.0-0.5% in placebo arm, p<0.0001. In fact, one review of the data
demonstrated increased bleeding rates in the conventional therapy group over placebo when
indirectly compared to all other DOAC trials, p= 0.0012. (Wu, Alotaibi, Alsaleh, Linkins, &
McMurtry, 2015) Wu et al. (2015) go on further to advocate the threshold for net benefit in
continuing DOAC may be lower than for VKA therapy and therefore provides a suitable lifetime
therapy.
A meta-analysis by Becattini and Agnelli (2016) also report all DOACs were, overall,
safer than conventional therapy. The primary outcome was similar between the DOAC groups
and conventional therapy groups; with the risk of recurrence reported as 4.1% patient-years
versus 4.4% patient-years for DOAC group and conventional therapy respectively. The review
goes as far as reporting DOAC to reduce all-cause mortality over conventional therapy with an
RR of 0.51. Several other incidental findings concerning primary outcome and safety outcomes
in subgroup populations. Apixaban was shown to be the safest DOAC evaluated in these studies
with the lowest bleeding risk showing a 69% reduction in qualifying bleeding episodes.
Dabigatran was found to be safer than conventional therapy in patients over the age of 60,
p=0.0099. Dabigatran is unique among all anticoagulation agents in that it continued to convey
anticoagulation protection up to one year after discontinuing therapy.
A Berger et al. (2015) retrospective study assessed the efficacy and safety of rivaroxaban
in first time unprovoked VTE. These patients received treatment beyond the initial three months
of recommended conventional therapy with rivaroxaban. Recurrent VTE in the treatment group
was 0.57% versus 1.19%, 1.07% versus 2.10% and 1.45% versus 2.60% at three, six, and 12-
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month follow-up intervals for treatment and placebo respectively. No increased risk of bleeding
was demonstrated in the treatment group versus the placebo group at three, six, and 12-month
intervals.
EINSTEIN DVT and EINSTEIN PE were open-label trials that established the dose
strength of therapy when compared to enoxaparin and warfarin for extended therapy based upon
risk factors warranting an extension of anticoagulation therapy (EINSTEIN Investigators, 2012
and 2010). Both studies showed rivaroxaban to be non-inferior to conventional therapy in terms
of reported recurrence and an approximate 50% reduction in major bleeding events. The major
bleeding used was the ISTH (International Society on Thrombosis and Haemostasis) definition
of major bleeding, however, these studies did have different definitions of clinically relevant
nonmajor bleeding (Cohen & Bauersachs, 2019). The XALIA-LEA was a companion study that
enrolled both DVT and PE patients. The findings of this retrospective study were consistent with
prior results in other studies.
A HOKUSAI-VTE review by Joseph and Bartholomew (2017) validated edoxaban’s
status as non-inferior with conventional therapy, with HR 0.89, and reduced bleeding risk with
RR of 0.81. Edoxaban and warfarin were not directly compared in this study.
A comprehensive review of existing DOAC trials and demonstrated with pooled results,
DOAC efficacy, with a 2.8% report of recurrence in therapy groups, p<0.0001, with an
annualized event rate of 6.0% versus 1.7% in placebo and DOAC treatment groups respectively
(Marik & Cavellazzi, 2015). Moodley and Goubran (2015) reiterated this finding. Their review
found reported bleeding rates of rivaroxaban, apixaban, and conventional therapy as 0.49%,
0.28%, and 0.89% respectively. This review reported fewer intracranial hemorrhage or
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gastrointestinal bleeding episodes in those receiving dabigatran versus first-time conventional
therapy recipients.
A Cochrane Review (Robertsen & McCaslin, 2015) was conducted, and it was the first
review assessing the efficacy and safety of oral anticoagulants in the prevention of recurrent
pulmonary embolism. The same oral anticoagulants have been assessed in other meta-analysis
but none of those directly evaluated these agents with pulmonary embolism.
The meta-analysis revealed no statistically significant differences in efficacy between
oral direct thrombin inhibitors (DTI) dabigatran and conventional anticoagulation therapy,
warfarin (VKA). Due to substantial heterogenicity in the two studies evaluating factor Xa
inhibitors, apixaban, edoxanban, and rivaroxaban, no meaningful conclusions can be drawn
regarding their efficacy.
Analysis of the data shows no differences in reported major bleeding between DOACs
and conventional therapy. The studies used strict bleeding guidelines set forth by the
International Society on Thrombosis and Haemostasis, ISTH.
Robertson and McCaslin were unable to comment on subgroup analysis; as some studies
failed to provide necessary patient-level data. Clinical decision-making should rely on patient
comorbidities and individual patient risks rather than generalities of care of certain diseases.
This Cochrane Review concluded a low risk of bias in the studies included in their metaanalysis. All the studies were, however, funded by the pharmaceutical companies in which the
evaluated drug was created. Speculation as to how this could lead to bias includes an altered
timeframe for reportable safety outcomes. All studies used computerized randomization but do
not elaborate leading to group selection bias. The quality of evidence for DTI versus
conventional therapy was graded high. The quality of evidence comparing factor Xa inhibitors to
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conventional therapy was graded moderate as the level of homogeneity of the participants was
not adequately explained. The quality of evidence for all-cause mortality was graded moderate as
only one study included this outcome. The evidence for major bleeding remained high due to
consistent and precise effect estimates. A major limiting factor in this review is the small number
of included studies at five, however, the number of participants included in each trial was
adequate.
The Robertson and McCaslin (2015) concluded the evidence do not adequately
demonstrate the replacement of conventional therapy with DOACs. However, they feel these
medications present a reasonable alternative to conventional therapy. Fixed dosing, ease of
administration, lack of routine lab monitoring may provide these medications as attractive
alternatives to conventional anticoagulation therapy. One point of significance at the time of
publishing was the lack of adequate antidotes for DOAC and presents a serious hurdle in their
use in the real world. The half-life of these medications is short but having a reversal agent will
only add to the argument for their use.
A subsequent Cochrane Review (Roberston, Yeoh, & Ramli, 2017) was conducted to
evaluate the efficacy of extended duration pulmonary embolic prophylaxis. Five studies and a
total of 5000 participants were included in this meta-analysis. No evidence was found which
showed favorability for extended prophylaxis over placebo in terms of prevention of recurrent
VTE, death, bleeding, or serious side effects such as myocardial infarction or stroke. Subgroup
analysis demonstrated placebo may be favorable over aspirin in the prevention of recurrent VTE.
In one study, rivaroxaban was shown to be more effective than aspirin in the prevention of
recurrent VTE while demonstrating no major differences in bleeding. Only one study compared
prophylactic agents against one another.
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Robertson et al. (2017) determined, at present, insufficient data is available to conclude
the efficacy and safety of VTE prophylaxis treatment in first time unprovoked VTE with any
agent. All studies included used strict bleeding guidelines set forth by the International Society
on Thrombosis and Haemostasis. All studies included used similar drug concentrations in the
treatment groups. Patient homogeneity was achieved across all trials due to strict inclusionary
criteria and statistical heterogeneity was low in all outcomes measured except recurrent VTE.
The timeframe for measuring outcomes varied greatly in the trials, varying from nine months to
37 months. Studies also varied in the timing of measured outcomes. Some measured outcomes at
the end of the treatment period, whereas others measured the outcome near the end of treatment.
This difference could potentially alter the efficacy reported upon discontinuation of the treatment
during follow-up. The total number of participants across the six studies examined was relatively
small and analysis was based upon 3,436 participants. The authors were unable to comment on
any subgroup analysis as some studies failed to provide necessary patient-level data.
Regarding extended prophylaxis versus placebo and for recurrent VTE and all-cause
mortality the evidence was graded moderate accounting for concerns arising from increased risk
of bias in individual studies. All other outcomes form the review; VTE-related mortality,
bleeding, stroke, and other serious adverse effects, the quality of evidence was low due to
substantial risk of selection bias and concerns over imprecision with wide confidence intervals
pertaining to the estimated effect and the small number outcome events. Data that compared
different prophylactic agents to one another was graded moderate due to imprecision, a low
number of outcome events, and wide confidence intervals reported. There was only one study in
which agents were compared to one another, and it did not demonstrate selection bias. Two
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studies included participants under the age of 18, but the mean age of the participant was 67; the
influence of those non-adult participants was negligible.
Robertson et al. (2017) were unable to offer a definitive opinion regarding extended VTE
prophylaxis with any agent due to the inadequately low numbers of the eligible studies. There is
a need for larger studies that use a stricter methodology in the assessment of the question of
prophylaxis. Any future studies should include groups of patients at the highest risk of recurrence
and a high risk of bleeding, which would reflect real-world demographics.

Discussion
The results of these studies demonstrate aspirin’s potential as an anticoagulation agent.
Moodley and Goubran (2015) argue, with a relative risk reduction of 42% in pooled data, aspirin
looks to be a quality agent in the prevention of VTE recurrence. Several key issues were noted,
however, for example demographic discrepancy between the WARFASA and ASPIRE groups.
The WARFASA group tended to be older (average age 62), male (63%), and a smoker. Whereas
the ASPIRE group the average age was 54 and 54% were male and non-smokers. Male sex,
increasing age, and smoking status are all known risk factors for coagulopathies. With a deeper
analysis of the participants, it can be speculated that the increased efficacy of the WARFASA
group is due to an increase in risk factors requiring anticoagulation, thus possibly inflating
reported success rate. This discrepancy can also explain the statistically insignificant difference
in the primary outcome found in the ASPIRE group, these folks were already less likely to
require anticoagulation due to fewer risk factors. Group bias may explain potential
cardioprotective properties demonstrated in the ASPIRE trial; as the atherosclerosis risk factors
are similar in those for pulmonary embolism. The retrospective chart review failed to show a
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reduction in primary outcomes for those receiving aspirin therapy, but since withholding aspirin
for those with atherosclerosis is morally dubious, no definitive conclusion can be made about the
protective element of aspirin therapy.
Aspirin does have a place within the anticoagulation decision algorithm. It is a suitable
alternative to DOAC and warfarin in patients with one or fewer risk factors. It may also present a
safer option for fragile patients requiring indefinite therapy, where warfarin or DOAC are
contraindicated or inappropriate based upon extrinsic factors. Patients with significant
comorbidities consideration are those with liver or kidney failure and other fragile patients.
Additional studies will be needed to evaluate long-term therapy to compare to DOAC to specific
subgroup populations which require anticoagulation. Future studies will need to adequately
power their research to examine bleeding risks with a comprehensive and well-defined bleeding
outcome. Discrepancies in data can be attributed to differences in group demographics and future
studies could equalize these differences for more robust results.
The efficacy of conventional warfarin therapy is well established within the literature.
The question is not, if this agent is effective, but rather, is the patient equipped to handle this
medication, and if so, how long should anticoagulation take place? The data suggests the longer
a patient is on warfarin the greater the risk for bleeding. One important factor in selecting
conventional therapy is warfarin has an antidote in vitamin k. It is readily available and cheap to
administer. Warfarin, itself, is cheap, accessible, and has a long half-life. Some of the issues with
warfarin are compliance concerns. A Moodley and Goubran (2015) review found a 79.9% noncompliance rate for target INR: 2.0-3.0. The same study reports a 51.5% discontinuation rate
against medical advice. Also, frequent monitoring with multiple dosage adjustments can
complicate administration for many patients. Warfarin also has many drug-drug interactions and
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requires patients to avoid certain foods. All these issues presents a major challenge for providers
in maintaining patient compliance. One possible alternative is low-dose warfarin with reduced
INR 1.5-1.9 (Jiang et al., 2017) The reduction in dose does convey some protection, albeit
significantly lower than conventional dosing, but allows for alternating monthly monitoring with
reduced dose adjustments. Data overwhelmingly has shown warfarin compliance will reduce
recurrent VTE, but it appears the risks must be weighed on a patient-to-patient basis when
considering indefinite therapy.
The conclusion of current data indicates newer anticoagulant agents like rivaroxaban,
edoxaban, apixaban, and dabigatran are just as effective as conventional warfarin therapy with
statistically similar rates of PE recurrence. In his review, Bauersachs (2016) noted the DOAC
studies showed a 0.4-1.2% for VTE recurrence in the treatment arms and 5.6-8.8% recurrence
rate in the placebo arms. Safety outcomes in this review indicate similar outcomes with reported
bleeding and bleeding mortality of 0.1-0.7% in the treatment arm versus 0.0-0.5% in the placebo
arms, p<0.0001. The Berger et al. retrospective review of rivaroxaban showed statistically
significant improvements at incremental follow-up periods in extended duration anticoagulation
therapy over placebo, all without demonstrating any increased risk for bleeding in the treatment
group.
Despite conclusions of DOAC studies, two separate Cochrane Reviews directly examined
the efficacy of these newer medications and their safety profile. Both Cochrane reviews found
the evidence moderately convincing with some concern over population selection and trial size.
Both the 2015 and 2017 Cochrane Reviews indicated several areas of future needs to upgrade
recommendations. Both Cochrane Reviews also indicate additional studies are needed to
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evaluate the long-term effects, as well as direct head-to-head comparisons of these newer agents
with conventional therapy.
Many fragile patients were not included in the DOAC studies; fragile is defined as over
75 years old, reduced CrCl (creatinine clearance) <50, or bodyweight below 50 kg. Patients less
than 50 kg and those over 100 kg were also not adequately represented across trials. Apixaban is
to be avoided in patients with CrCl <25, as all other DOACs are not recommended for renal
patients with CrCl<30. These exclusions could have contributed to favorable results in primary
efficacy outcomes as well as improved safety profile results, as the study participants tended to
be younger and have fewer co-morbidities. The strict inclusionary criteria for these studies were
not indicative of real-world patients and the resulting data may not translate to real-world fragile
patients.
Most studies did not exclusively evaluate first-time pulmonary embolism patient. Patients
with deep vein thrombosis (DVT) and cancer patients were included as well. With similar
pathophysiology, authors reasoned the inclusion of DVT patients within these studies. The
severity of disease status is much higher in first-time unprovoked PE than DVT. Only one review
parsed out the pulmonary embolism data away from general group data. The risk of recurrence
between DOAC and VKA was statistically similar 2.4% versus 2.6% OR 0.89%; CI 95%. This
analysis also showed a 50% reduction in major bleeding with the DOAC group over the VKA
group. However clinically significant rates of bleeding between DOACs and VKA were similar,
10.2% versus 11.3%; OR 0.89 95% (Becattini & Agnelli, 2016)
Lead-in therapy for these studies was not homogenous across the studies. Agents used as
lead-in therapy and their duration varied from study to study. Therapy duration was not uniform
in any of the DOAC studies and follow-up periods also varied across studies which may provide

ANTICOAGULATION EFFICACY AND SAEFTY

19

a potential in reporting bias in both efficacy and safety categories. Varying approaches to lead-in
therapy included; a single drug approach or multidrug approach. The multidrug approach used
conventional therapy during the initial three months following the insult then switching to
second medication during the extended therapy.
The role of warfarin in anticoagulation therapy is well-established and effective. The
issue resides in the side effect profile, risk of major bleeding, and patient compliance. The risks
and compliance challenges increase with aging patients. Providers and patients must reassess
risk/benefit regularly. Aspirin’s role has been evaluated and is considered inferior to both DOAC
and conventional therapy but does convey some protection. The declaration of DOAC as a
wholesale replacement to conventional anticoagulation therapy is grossly overstated. Indirect
drug comparison studies have used to establish non-inferiority of DOACs. There are many
questions concerning the strict exclusionary criteria employed in these studies which may not
reflect accurate results when applied to real-world patients.
Additional trials are needed to evaluate the efficacy and safety profile of DOAC directly
against conventional therapy. The RE-MEDY trial was the only included trial to evaluate
dabigatran against conventional therapy. Elmi, Di Pasquale, & Pesavento (2017) review of the
RE-MEDY trial did show improved safety profile of dabigatran over warfarin when directly
compared; 5.6% reported major bleed or clinically relevant bleeding in the dabigatran group
versus 10.2% report in warfarin group, p =0.06, with similar rates of recurrence 1.8% versus
1.3% in dabigatran and warfarin respectively. A yet to be published clinical trial has been
submitted for approval and is titled COVET (Comparison of Oral Anticoagulants for Extended
Venous Thromboembolism) which will directly warfarin to apixaban and rivaroxaban to
compare safety outcomes and reduction of recurrent VTE. Additional trials are also needed to
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evaluate the long-term efficacy and more importantly risks associated with indefinite
anticoagulation therapy. Current issues regarding data inconsistency across study groups which
prevents a direct comparison. Varied trial length and inconsistent follow-up schedules varied
from one trial to the next. Heterogenous lead-in therapy is another valid concern of these studies
used to prove the safety and efficacy of DOACs. Future studies would benefit to normalize leadin duration and agent employed. Standardized follow-up periods could also help eliminate
potential bias in safety and efficacy reporting. More accurate representative trial populations with
looser exclusionary criteria would allow for stronger recommendations for the use of DOAC
therapy instead of conventional therapy. As of this review, DTI and Factor Xa inhibitor classes
provide an alternative to conventional therapy with moderate recommendations at most.
Applicability to Clinical Practice
The purpose of this research was to assist in simplifying the decision-making process
when considering anticoagulation therapy specifically after unprovoked pulmonary embolism.
The risks associated with anticoagulation continue throughout the duration of therapy, which is
typically indefinitely in the case of unprovoked pulmonary embolism. Whether on therapy or if
the patient forgoes treatment risk is expected. Currently, patients and providers perform a
risk/benefit analysis to weigh the risks of therapy versus the risk of recurrence. There are many
factors that must be examined. The hope was to find evidence in the literature to ease the burden
shared decision-making. Unfortunately, the data does not bear out a definitive answer; in respect
to either agent or duration. On the other hand, the data does suggest some protection with newer
DOAC or aspirin therapy in certain population subgroups where conventional therapy is deemed
unsatisfactory. Unfortunately, additional studies are warranted and until more concrete
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information becomes available an individual approach to anticoagulation is the best-practices
approach.
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